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Background We conducted a phase II trial of erlotinib in patients with 
advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth 
factor receptor (EGFR) mutations, and evaluated the relationship between 
plasma concentration and efficacy of erlotinib. 
Methods Patients who were previously treated but naive to 
EGFR-tyrosine kinase inhibitors, with advanced NSCLC harboring EGFR 
mutations, were enrolled. Erlotinib was given at 150 mg once daily until 
disease progression. The primary end point was objective response rate 
(ORR). Plasma trough levels of erlotinib were measured on Days 2 (D2) and 8 
(D8) by high-performance liquid chromatography. 
Results In total, 29 patients were enrolled from September 2008 to 
January 2011. ORR was 61.5% (95% confidence interval [CI] 40.57-79.8) of 
26 assessable patients. The median progression-free survival (PFS) and 
overall survival (OS) were 6.3 months and 16.9 months, respectively. Skin 
rash was observed in 24 patients, mostly at grade 1 or 2. Grade 2 
pneumonitis was observed in one patient. We collected blood samples from 
16 patients. The median PFS of the high and low D8/D2 ratio group was 11.2 
months and 5.7 months, respectively (p= 0.044, hazard ratio=0.301, 95% CI, 
0.094-0.968). 
Conclusion Erlotinib showed an ORR comparable to that seen in previous 
studies for patients with NSCLC harboring EGFR mutations, although 
response, the primary end point, did not reach the predetermined threshold 
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level. The D8/D2 ratio of erlotinib plasma trough levels might be a predictive 
factor for PFS. 
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Molecular-targeted anti-cancer agents are designed to act selectively on the 
target that promotes proliferative signals in cancer cells. Various such 
agents are available, with the epidermal growth factor receptor 
(EGFR)-tyrosine kinase inhibitor (TKI) attracting particular attention. 
EGFR is a member of the receptor tyrosine kinase family and is found mainly 
on the surface of epithelium cells. After ligand binding to the extracellular 
domain of EGFR, the transmembrane receptor forms dimers, activating 
intrinsic tyrosine and autophosphorylating tyrosine residues in its 
cytoplasmic domain, thereby triggering a cascade that leads to cellular 
proliferation, angiogenesis, metastasis, and inhibition of apoptosis [1]. EGFR 
is frequently overexpressed in several malignancies such as head and neck, 
breast, lung, ovary and colon [2]. 
Mutations in exons 18 to 21 of the EGFR tyrosine kinase domain have 
been reported to be significantly associated with the clinical effects of 
EGFR-TKIs [3, 4].In lung cancer cells, many types of mutation have been 
identified in this area, but a deletion in exon 19 and a point mutation in exon 
21 account for 90% of all mutations. Recently, the results of two randomized 
phase III trials of erlotinib have been published. In both trials, erlotinib was 
compared with platinum-based chemotherapy in a first-line setting for 
patients with non-small-cell lung cancer (NSCLC) harboring EGFR 
mutations. A European trial revealed that median progression-free survival 
(PFS) was 9.7 months in the erlotinib group and 5.2 months in the 
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platinum-based chemotherapy group (hazard ratio 0.37, p<0.0001) [5]. A 
Chinese trial also revealed median PFS to be significantly longer in 
erlotinib-treated patients than in those receiving platinum-based 
chemotherapy (13.1 months vs. 4.6 months; hazard ratio 0.16, p<0·0001) [6]. 
These data suggest that these EGFR mutations are also predictive factors for 
response to erlotinib. 
As mentioned above, erlotinib has come to be recognized as highly effective 
for patients with NSCLC harboring EGFR mutations. However, even 
patients who initially respond to EGFR-TKIs will eventually relapse. 
Acquired resistance mechanisms for EGFR-TKIs have been reported, 
including a T790M point mutation [7, 8], MET amplification [9] and 
hepatocyte growth factor overexpression [10]; however, it remains unclear 
what accelerates the acquirement of EGFR-TKI resistance for each patient. 
Nakamura et al. have described the relationship between the effects of 
gefitinib and its plasma concentration [11]. They concluded that the ratio of 
the gefitinib plasma trough levels on Day 8 (D8) and Day 3 (D3) might 
influence PFS. In accordance with this result, we designed a phase II trial of 
erlotinib in patients with advanced NSCLC harboring EGFR mutations, who 
had been previously treated but were naive to EGFR-TKIs, to evaluate 
whether the ratio of early and late plasma trough levels of erlotinib might be 
useful for predicting its efficacy and toxicity. 
 
Patients and methods 




The eligibility criteria for this study were as follows: histologically or 
cytologically confirmed stage IIIB or IV NSCLC; progressed or relapsed after 
one or two regimens of chemotherapy without EGFR-TKIs; measurable or 
evaluable disease; presence of activating EGFR mutation; Eastern 
Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2; 
adequate bone marrow function; adequate liver function; serum creatinine 
below the upper limit of normal; age older than 20 years. The exclusion 
criteria were superior vena cava syndrome, clinically significant cardiac 
disease, uncontrolled diabetes mellitus and hypertension, concomitant active 
malignancy, and serious infection. Interstitial pneumonia or pulmonary 
fibrosis was excluded. Pregnant or lactating women were also excluded. The 
smoking history of the patients was obtained at baseline, and patients were 
categorized as those who had never smoked (smoked fewer than 100 
cigarettes in lifetime), former smokers (smoked more than 100 cigarettes in 
lifetime and more than 1 year since cessation), or current smokers (still 
smoking or less than 1 year since cessation). 
Written informed consent was obtained from all patients before 
treatment. The study protocol and informed consent procedures were 
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All patients were treated once daily with 150 mg erlotinib. The treatment 
was continued until disease progression, development of intolerable toxic 
effects, or withdrawal of consent. Erlotinib dose reduction to 100 mg/day, or 
interruption up to 14 days, was allowed in the case of 3 or 4 adverse events.  
A second dose reduction was not allowed. If any grade of interstitial lung 
disease occurred, erlotinib was stopped and the patient was immediately 
treated with corticosteroid. 
 
Evaluation of tumor response and toxicities 
Complete blood cell counts and blood chemistry studies were done at least 
twice a week for the first 4 weeks of the treatment. Chest radiography was 
performed at least twice in the first month of treatment. We repeated a 
computed tomography (CT) scan of the chest every 4 weeks until treatment 
end. We repeated a complete blood count and blood chemistry studies every 4 
weeks after the first month until treatment end. Additionally, adequate 
surveillance, such as CT, magnetic resonance imaging (MRI), positron 
emission tomography (PET), and bone scintigraphy, was performed 
immediately if the treating physician suspected disease progression. The 
response was investigator-determined according to the Response Evaluation 
Criteria in Solid Tumors (RECIST) version 1.0 [12]. All adverse events and 
serious adverse events were recorded and classified by grade according to the 
Common Terminology Criteria for Adverse Events version 3.0 (CTCAE 
ver3.0). 




Plasma concentration of erlotinib 
Blood samples were taken from patients from whom written informed 
consent had been obtained before treatment. We additively analyzed the 




We obtained blood samples in heparinized tubes at baseline (Day 0) and just 
before administration of erlotinib on the morning of Day 2 (before the second 
administration) and Day 8 (before the eighth administration). Plasma was 
isolated by centrifugation at 3000 g at 4°C for 5 minutes and stored at −20°C. 
Then, samples were deproteinized using an equal volume of acetonitrile and 
centrifuged at 15,000 g at 4°C for 5 minutes. The plasma samples were 
stable for at least 6 months at less than −20°C.  
 
Measurement of the Plasma Concentration of Erlotinib 
The plasma trough levels of erlotinib were measured by the 
high-performance liquid chromatography (HPLC) method reported by 
Uesugi et al [13]. The HPLC system consisted of a JASCO PU-1580 pump, a 
JASCO 870-UV UV/vis detector (JASCO Inc., Tokyo, Japan), and a Shimazu 
C-R4A integrator (Shimazu, Kyoto, Japan). Isocratic elutions were 
performed using an Inertsil ODS-3 column (5 µm, 4.6 mm I.D. × 150 mm; GL 
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Sciences Inc., Tokyo, Japan). The ultraviolet detection wavelength was 340 
nm. The mobile phase consisted of 0.1 M triethylamine (TEA)-H3PO4 (pH 
8.0)-acetonitrile-tetrahydrofuran (THF) (60:40:2, v/v/v). The flow rate was 




The primary endpoint was overall response rate (ORR). A two-stage accrual 
design was chosen to define the total number of patients required for this 
study. Assuming an ORR of 40% for standard therapy, a target response rate 
of 70% was established. Alpha = 0.05, beta = 0.10, and the estimated 
required number of patients was more than 24. If six or more patients had 
not achieved PR in an interim analysis when ten patients had been accrued, 
the study would be discontinued. The secondary endpoints were PFS and 
overall survival (OS). PFS was defined as the time from start of treatment to 
the date of disease progression or death. OS was calculated from the start of 
treatment to death or the last follow-up visit. 
Univariate analysis was used to assess the contribution of each variable 
to ORR and survival. The survival curves were plotted by the Kaplan-Meier 
method and differences between groups were analyzed by the log-rank test. A 
two-tailed p < 0.05 was considered to indicate significance. 
 
Results 




From September 2008 through January 2011, 29 patients with advanced 
NSCLC harboring EGFR mutations were enrolled. By the time ten patients 
had been accrued, five patients had achieved PR in an interim analysis. 
Three patients were ineligible because they had no history of prior 
chemotherapy. Table 1 lists the baseline characteristics of the 26 assessable 
patients, all of whom had adenocarcinoma. Twenty-four patients (92.3%) 
were PS 0 or 1. Sixteen patients (61.5%) had never smoked. Twenty-three 
patients (88.4%) received erlotinib as second-line treatment, and three 
patients as third-line treatment. 
 
Response and survival 
The median treatment duration was 5.5 months (range, 0.2 to 17.0 months). 
Treatment was continued until progressive disease (PD) in 20 patients and 
interrupted in five patients: two refused further treatment due to rash 
(Grade 1 and 2), two showed drug-related toxicities, grade 3 rash and grade 3 
fatigue, and one had grade 2 pneumonitis. Of 26 assessable patients, 2 had 
complete response (CR; 7.7%), 14 had partial response (PR; 53.8%), 4 had 
stable disease (SD; 15.3%), and 6 had PD (23.1%). The ORR and disease 
control rate was 61.5% (95% confidence interval [CI] 40.6-79.8) and 76.9%, 
respectively. 
At the time of analysis, 24 patients had had disease progression and 15 
had died. The median PFS and OS were 6.3 months (95% CI, 0.5- 16.5) and 
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The most common adverse events were skin rash in 24 patients (92.3%) with 
23 patients classified as grade 1 or 2 and one patient classified as grade 3, 
and diarrhea in eight patients (30.8%) with all classified as grade 1 or 2. 
Grade 3 or 4 adverse events were observed in four patients: fatigue in three, 
nausea in one and rash in one (simultaneous fatigue and nausea in one 
patient). Two patients did not return to treatment after interruption, but the 
rest continued until PD. Grade 2 pneumonitis occurred in one patient, and 
we stopped treatment immediately and it recovered with corticosteroid 
treatment. Dose reductions were required in eight patients because of rash 
(five patients), diarrhea (one patient), nausea (one patient), and stomatitis 
(one patient). All of these toxicities were grade 1 or 2, but the patients 
wanted to reduce the dose of erlotinib. Two refused to continue the treatment 
even with the dose of erlotinib reduced to 100 mg/day. A total of five patients 
failed to continue treatment until PD. 
 
Plasma Concentrations 
We obtained informed consent for blood sampling from 16 of 26 eligible 
patients in this phase II study, and additively analyzed the plasma trough 
levels of erlotinib. The median age of the 16 patients was 66 years (range, 
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56-83). They had PS 0 or 1, and six of them were current or former smokers. 
All of them received erlotinib as second-line therapy. Their characteristics 
are summarized in Table 2. Of the 16 patients, 12 responded to erlotinib, two 
had SD, and two had PD. Median PFS was 10.2 months (95% CI, 0.5-15.7), 
and median OS was 22.7 months (95% CI, 0.8; not reached). The median 
plasma trough levels was 1.35 μg/ml (range, 0.68–2.55 μg/ml) on D2 and 3.06 
μg/ml (range, 1.80–6.93 μg/ml) on D8. These data were comparable to 
previously reported data [14, 15]. Table 3 shows the results of univariate 
analysis of PFS. D8/D2 ratio was a significant factor for PFS (p = 0.044, HR = 
0.301, 95% CI, 0.094-0.968), while sex, age, smoking status and the plasma 
trough levels of erlotinib on D2 and D8 were not significant. Figure 1 shows 
PFS curves stratified by D8/D2 ratio. We defined a high D8/D2 ratio as being 
above the median value. The median PFS of the high and low D8/D2 ratio 
group was 11.2 months and 5.6 months, respectively. 
D8/D2 ratio was not significant in OS (p= 0.604). Sex, age, smoking status 
and plasma trough levels of erlotinib on D2 and D8 were also not significant 
(D2, p = 0.078 and D8, p = 0.931). 
Nine of these patients showed grade 2 or higher adverse events. The 
D8/D2 ratio was not statistically significantly related to these adverse events 
(p= 0.751). Plasma trough levels of erlotinib on D2 and D8 were also not 
significant (D2, p = 0.751 and D8, p = 0.931). 
 
Discussion 
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We prospectively evaluated the efficacy and toxicities of erlotinib in patients 
with advanced NSCLC harboring EGFR mutations. We found an ORR of 
61.5%, a median PFS of 6.3 months and OS of 16.9 months. Although this 
ORR is much higher than that of standard second-line chemotherapy in 
patients with advanced NSCLC, it did not reach the predetermined threshold 
level. There are few comparable ORR data from prospective phase II trials of 
erlotinib in patients with advanced NSCLC harboring EGFR mutations. 
Rosell et al. revealed that 80 of 129 patients with advanced NSCLC 
harboring EGFR mutations had responded to erlotinib (ORR is 68.9) in their 
cohort study [16]. In EURTAC, which was performed in a first-line setting, 
ORR was reported as 64% [5]. Thus, our result is comparable to previous 
reports. 
Here, four patients experienced grade 3 or higher adverse events and 5 
patients withdrew from erlotinib treatment due to adverse events. Skin rash 
was observed in 25 patients (96%) and was a major cause of discontinuation 
and dose reduction, though we tried to manage it in accordance with the 
guidelines [17]. Patients’ median age was 72 years in this trial, which is 
relatively high compared with other prospective trials. Elderly patients 
(more than 70 years old) experienced more severe toxicities than younger 
patients and required dose reductions and treatment discontinuations in 
BR.21 [18]. Elderly patients, compared with young patients, had 
significantly more severe (grade 3 and 4) toxicity (35% vs 18%; p< 0.001), 
were more likely to discontinue treatment due to toxicity of erlotinib (12% vs 
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3%; p< 0.0001), and had lower relative dose intensity (64% vs 82% received 
>90% planned dose; p< 0.001). 
Yeo et al. reported impressive response rates with erlotinib at a dose of 
25 mg/day, and no patients discontinued because of adverse events [19]. No 
statistically significant increase in plasma concentration of erlotinib was 
observed in patients aged 70 years and older in this trial (data not shown), 
but 150 mg/day might be too high a dose for elderly patients. 
In this trial, the patients with advanced NSCLC harboring EGFR 
mutations who showed a high ratio of D8/D2 plasma trough levels of 
erlotinib had a superior PFS, though sample size was limited. This suggested 
that patients who show a rapid increase in plasma trough levels from the 
treatment start to the achievement of steady state should show a better 
response duration. This gradient of increase in the plasma trough levels 
corresponded to the “accumulation factor”. This is the ratio of the plasma 
concentration at t1 after the first administration of the drug to the plasma 
concentration at steady state. In this trial, t1 is 24 hours and D2 is 
equivalent to the plasma concentration at t1 after the first administration of 
the drug. It is also considered that D8 (plasma trough level of erlotinib after 
the seventh daily administration) is an approximate value of the plasma 
trough level at steady state. Thus, D8/D2 in this trial is equivalent to the 
accumulation factor. 
Alternatively, the accumulation factor can be given as 1 / (1-e-k･τ) where k 
is an elimination rate constant and τ is the dosing interval. Thus, 
Motoshima et al. Page  15 
 
 
considering our results, a shorter dosing interval, for example two or three 
times daily, might improve the response period of erlotinib. 
Additionally, our results were similar to those of a previous report about 
gefitinib. Nakamura et al. also reported that the patients with advanced 
NSCLC who showed a high ratio of D8/Day 3 (D3) plasma trough levels had 
good PFS, although the individual plasma trough levels on D3 and D8 did 
not affect PFS [11]. They suggested that the metabolism of gefitinib might 
affect its response duration. Oral EGFR-TKIs were dramatically effective for 
patients with NSCLC harboring EGFR-sensitive mutations [8, 9, 20, 21], and 
some patients responded to the treatment for more than 2 or 3 years. This 
long response duration might result from a high accumulation factor of 
EGFR-TKI. The sample size of our study was limited: further investigation is 
necessary to clarify the relationship between the response duration and 
accumulation factor of erlotinib. 
In conclusion, our trial showed erlotinib to have similar efficacy to 
that seen in previous studies in patients with NSCLC harboring EGFR 
mutations. In addition, it suggested that the D8/D2 ratio of the trough 
plasma concentrations of erlotinib might predict its anti-tumor activity. 
Further pharmacokinetic study is needed to confirm the relationship 
between the plasma concentration parameters of erlotinib and its anti-tumor 
activity. In addition, to improve the response period of erlotinib, we should 
re-evaluate the dosing interval from a pharmacokinetic viewpoint.
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Table 1 Characteristics of patients with non-small-cell lung cancer 
treated with erlotinib 
Characteristics n = 26 
Age (years), median (range) 72 (56-83) 
Sex  
  Male 12 
  Female 14 







Prior lines of chemotherapy  
One 23 
Two 3 
Smoking status  
Current or ever smoked 10 
Never smoked 16 




del 19 10 
L858R 13 
Both del 19 and L858R 3 
ECOG, Eastern Cooperative Oncology Group; PS, performance 






Table 2. Characteristics of patients who agreed to blood sampling 
Characteristics n = 16 
Age (years), median (range) 66 (56-83) 
Sex  
  Male 4 
  Female 12 







Prior lines of chemotherapy  
One 13 
Two 3 
Smoking status  
Current or ever smoked 6 
Never smoked 10 
EGFR mutation  





Both del 19 and L858R 1 
ECOG, Eastern Cooperative Oncology Group; PS, performance status; EGFR, 





Table 3. Results of Univariate Analysis of Prognostic Value to 
Progression-Free Survival 
Factors Hazard Ratio 95% Confidence 
Interval 
p 
Sex, female 0.730 0.230-2.32 0.594 
Age, <70 years 2.308 0.821-6.486 0.113 
Never smoked 1.373 0.471-4.007 0.562 
D2, high 0.330 0.1055-1.033 0.057 
D8, high 1.213 0.4371-3.366 0.711 
D8/D2, high 0.301 0.094-0.968 0.044 
 
 
 
